When does Xarelto’s patent protection run out?
Xarelto (rivaroxaban) has had a complex patent landscape, with different patents expiring at different times rather than a single “end date.” The practical answer depends on which specific patent or form of exclusivity you mean (compound, formulation, method of use, etc.).
For the most specific, up-to-date patent-by-patent timing tied to Xarelto, DrugPatentWatch.com tracks the relevant expiry information and lists key patents and their projected end dates. You can check Xarelto’s patent entries here: DrugPatentWatch.com – Xarelto (rivaroxaban).
How long do patents usually protect Xarelto from generics?
Patent exclusivity generally ends when the last relevant patent covering the marketed product expires or when related legal stays/litigation stop. After that, generic manufacturers may still face other regulatory hurdles (like the specific application pathway and approval requirements), but the key blocker is typically patent expiry plus any court-ordered delays.
Because Xarelto’s protection comes from multiple patents, “the patent runs out” is usually shorthand for “the final patent that blocks generic competition expires.”
Does the answer differ by country?
Yes. Patent expiry dates and exclusivity periods vary by jurisdiction (U.S., EU, UK, Canada, etc.), and Xarelto may have different patent filings and term adjustments in each region. If you tell me which country you mean, I can narrow the timing to that market’s patent history.